Fifty-four hospitalised and outpatients with a DSM 111 diagnosis of major depressive disorder and 21-item HPRSD score of 2 18, were randomised to 5 weeks' of treatment with either Org 3770 (n=27; 20-60mg/day) or placebo (n = 27). The treatment with Org 3770 resulted in statistically significant and
A double-blind placebo-controlled study of Org 3770 in depressed outpatients
β Scribed by James L. Claghorn; Michael D. Lesem
- Book ID
- 119089873
- Publisher
- Elsevier Science
- Year
- 1995
- Tongue
- English
- Weight
- 586 KB
- Volume
- 34
- Category
- Article
- ISSN
- 0165-0327
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
In a controlled double-blind study, sulpiride 10G200mg daily or placebo was administered over a five-month period to 22 and 24 depressive elderly outpatients. The majority of the patinets in both groups were diagnosed as suffering from relatively mild degrees of depression, i.e. from dysthymic disor
The efficacy and tolerability of the new antidepressant Org 3770 were evaluated in a multicentre, double-blind, clomipramine-controlled trial. In total, 174 patients (126 women and 48 men), aged 18-75 years, who were suffering from a moderate or severe major depressive episode, were randomly assigne
Results are reported from a randomized, double-blind, trazodone-and placebo-controlled, 6 weeks' eficacy and safety study of a new antidepressant Org 3770 (RemeronB), in 150 outpatients over 55 years of age, with a DSM 111 diagnosis of moderate to severe major depressive disorder. On the 21-item HAM